Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $25

Goldman Sachs analyst Salveen Richter has downgraded Ultragenyx Pharmaceutical (NASDAQ: RARE) from a Buy rating to Neutral. The price target for the stock has been significantly reduced from $61 to $25.